Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer

A Single-Institution, Open-Label, Single-Arm phase1/2 Study of Measles Vaccine as Consolidation in Patients With Measles Virus-Positive, Stage 3B/4 Non-Small Cell Lung Cancer

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00828022

Acronym

SMC4692

Enrollment

Registered

2009-01-23

Start date

2009-03-31

Completion date

Unknown

Last updated

2009-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Measles, Non-Small Cell Lung Cancer

Keywords

measles-positive NSCLC, measles vaccine, consolidation, Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission

Brief summary

The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with pleural effusion) or metastatic (stage 4) tumors in remission.

Detailed description

This is a single-institution, non-randomized phase 1/2 study in patients with locally-advanced or metastatic NSCLC in remission after receiving standard systemic chemotherapy of four cycles of combination chemotherapy consisting of four cycles of cisplatin combined with vinorelbine.

Interventions

BIOLOGICALattenuated measles vaccine

4-week apart, two vaccines starting 4 weeks after last chemotherapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients in remission after first-line chemotherapy

Exclusion criteria

* Progressive disease

Design outcomes

Primary

Measure	Time frame
To assess progression-free survival (PFS) and overall survival (OS) in patients with NSCLC in remission receiving subcutaneous live-attenuated measles virus vaccine as consolidation therapy in patients with measles-positive tumors.	2-years

Secondary

Measure	Time frame
To evaluate additional measures of efficacy, safety, and disease/treatment-related symptoms.	2 years

Countries

Israel

Contacts

Primary ContactSamuel Ariad, MD

ariad@bgu.ac.il972-8-6400537

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026